What records are connected here?
- Evidence lanes
- 3
- Source years
- 17
- Drugs@FDA applications
- 2
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Large human trialsHormones · Sexual and reproductive health · Cancer
Goserelin is a lab-made decapeptide analogue of gonadotropin-releasing hormone (GnRH) and the active ingredient in Zoladex.1,2 FDA first approved Zoladex in 1989. The cited label covers prostate cancer, endometriosis, thinning the uterine lining before endometrial ablation, and advanced breast cancer in pre- and perimenopausal women.1,2 Its label describes randomized trials, including one of 466 men in which adding Zoladex and flutamide to radiation lowered local prostate cancer failure at four years.1
| What it is | A synthetic decapeptide analogue of GnRH that, with continued use, suppresses the pituitary’s release of reproductive hormones, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Zoladex with an original approval date of December 29, 1989. The cited label has no boxed warning.1,2 |
| Human evidence | Randomized and controlled trials in prostate cancer, endometriosis, abnormal uterine bleeding and breast cancer, described in the label.1 |
| Evidence strength | Large randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned |
Goserelin is a synthetic analogue of gonadotropin-releasing hormone (GnRH), the hypothalamic peptide that controls the pituitary’s reproductive hormones.1
In the United States it is the active ingredient of Zoladex, from TerSera Therapeutics, according to Drugs@FDA.2
The label states that goserelin acts as an inhibitor of pituitary gonadotropin secretion when given in its long-acting form, lowering testosterone in men and estrogen in women.1
In animal and laboratory studies, goserelin caused hormone-sensitive breast and prostate tumors to shrink or stop growing, according to the label. The label also notes that tumor symptoms can briefly worsen in the first weeks.1
In a controlled trial of 466 men with bulky prostate cancer, adding Zoladex and flutamide to radiation lowered the four-year rate of local failure from 33% to 16% and lengthened median disease-free survival from 2.6 to 4.4 years, according to the label.1
In two endometriosis trials, Zoladex was as effective as danazol at relieving symptoms, and 63% and 62% of women on Zoladex had at least a 50% reduction in lesions, according to the label.1
In a randomized trial of 358 women before endometrial ablation, 40% of those given Zoladex reported no menstrual periods six months after surgery, compared with 26% given placebo, according to the label.1
In premenopausal women with hormone-receptor-positive advanced breast cancer, interim data on 124 women in a randomized trial showed a 22% objective response with Zoladex versus 12% with removal of the ovaries, according to the label.1
Evidence-strength label: Large randomized human trials. How this label is assigned
Yes. Drugs@FDA lists Zoladex, application NDA 019726, with an original approval date of December 29, 1989.2
The Zoladex label cited here (DailyMed SPL version 9, published March 26, 2026) states that it is indicated for prostate cancer with flutamide and radiation, palliative treatment of advanced prostate cancer, endometriosis, endometrial thinning before ablation, and palliative treatment of advanced breast cancer in pre- and perimenopausal women.1
The label has no boxed warning. It states that Zoladex is contraindicated in pregnancy unless used for advanced breast cancer, and its warnings include tumor flare, high blood sugar, heart attack and stroke risk reported in men, and severe skin reactions.1
The label states that there is insufficient evidence to determine whether pregnancy rates are improved or harmed by its use.1
Results of the breast cancer comparison beyond its interim analysis: the label reports interim data from 124 women.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Goserelin: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Goserelin are a bounded selection, not every registration or paper about Goserelin. For the years before Goserelin was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Goserelin as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Goserelin in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Zoladex for prostate cancer, breast cancer and endometriosis. The label describes randomized and controlled trials in each approved use, including a 466-man prostate cancer trial and a 358-woman placebo-controlled trial before endometrial ablation.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Zoladex for prostate cancer, breast cancer and endometriosis. The label describes randomized and controlled trials in each approved use, including a 466-man prostate cancer trial and a 358-woman placebo-controlled trial before endometrial ablation.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 12, 2026
ClinicalTrials.gov record NCT07310420↗Added to PeptideScanner November 15, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT07310420↗Source date November 12, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT02115282↗Source date October 22, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT05161195↗Source date October 19, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
30 of 30 selected trial records include at least one phase value; 30 of 30 include a status value in the retained structured contract.
30 of 30 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT00004124 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-12-30, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT00005044 at 2026-11-15T21:50:32.222Z. Its registry update date was 2022-06-15, and PeptideScanner's reviewed identity mapping was goserelin.
PeptideScanner retained ClinicalTrials.gov record NCT00108732 at 2026-11-15T21:50:32.222Z. Its registry update date was 2015-06-30, and PeptideScanner's reviewed identity mapping was goserelin.
30 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span December 29, 1989 to November 12, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07310420 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was goserelin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02115282 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was goserelin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT05161195 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-19, and PeptideScanner's reviewed identity mapping was goserelin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02003209 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-10-06, and PeptideScanner's reviewed identity mapping was goserelin.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01723774 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was goserelin.↗
Literature metadata
PubMed lists PMID 42226753 in Drug design, development and therapy as Journal Article, Review, with publication-date metadata of 2026-05-27 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03671330 at 2026-11-15T21:50:32.222Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was goserelin.↗
Literature metadata
PubMed lists PMID 26131799 in Medicine as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2015-07 (month precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 15590321 in European journal of oncology nursing : the official journal of European Oncology Nursing Society as Journal Article, Review, with publication-date metadata of 2004 (year precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 21380781 in Medical oncology (Northwood, London, England) as Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2011-03-06 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 22265697 in The Lancet. Oncology as Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2012-01-20 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 23184499 in Breast cancer (Tokyo, Japan) as Clinical Trial, Journal Article, with publication-date metadata of 2012-11-25 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026